Related Experiment Video
Updated: May 6, 2026

Isolation and Characterization of Primary Rat Valve Interstitial Cells: A New Model to Study Aortic Valve Calcification
Published on: November 20, 2017
EP300/CREBBP induces osteogenic differentiation of valve interstitial cells by promoting the SPP1 expression in
Cheng Yu1, Ming Dong1, Danna Wu2
1Department of Cardiovascular Surgery, Hainan General Hospital (Hainan Affiliated Hospital of Hainan Medical University), Number Nineteen, Xiuhua Road, Xiuyin District, Haikou, 570311 Hainan People's Republic of China.
Abstract:
Secreted phosphoprotein 1 (SPP1) has been identified as a driver of fibrosis and inflammation, while its contribution to calcific aortic valve disease (CAVD) has not been clarified. In this research, we explored the possible role of SPP1 and the underlying molecular mechanism in CAVD. C57BL/6J mice were subjected to a high-fat diet (HFD), and human valve interstitial cells (VICs) were induced with the osteogenic medium (OM) for modeling. SPP1 was highly expressed in the human calcific aortic valve and VICs induced with OM, and its transcription was regulated by EP300/CREBBP. Knockdown of SPP1 inhibited the osteogenic differentiation of VICs, and overexpression of SPP1 reversed the repressive effect of EP300/CREBBP inhibitor on the osteogenic differentiation of VICs. EP300/CREBBP inhibitor ameliorated the aortic valve thickening and calcification in mice induced with HFD, and combined overexpression of SPP1 reversed the effect. In conclusion, the present findings suggest that EP300/CREBBP is dependent on SPP1 to induce osteogenic differentiation of VICs, thereby promoting the development of CAVD.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Mitral Regurgitation I: Introduction
Aortic Regurgitation I: Introduction
Aortic Regurgitation III: Medical Management
Cardiomyopathy III: Hypertrophic Cardiomyopathy

